Andexanet Alfa News
Andexanet Alfa currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Andexanet Alfa with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
- Evidence level: L5
- Predicted indications (20):
- Glanzmann thrombasthenia (99.8%)
- primary release disorder of platelets (99.8%)
- pseudo-von Willebrand disease (99.7%)
- hemophilia (99.1%)
- hemorrhagic disorder due to a constitutional thrombocytopenia (99.0%)
- bleeding diathesis due to a collagen receptor defect (98.9%)
- acquired coagulation factor deficiency (98.8%)
- Scott syndrome (98.7%)
- congenital prothrombin deficiency (98.4%)
- hereditary thrombocytosis with transverse limb defect (97.2%)
- familial thrombomodulin anomalies (97.1%)
- flood factor deficiency (97.1%)
- fetal and neonatal alloimmune thrombocytopenia (96.6%)
- platelet-type bleeding disorder (96.2%)
- methylcobalamin deficiency type cblG (94.6%)
- autosomal dominant macrothrombocytopenia (93.9%)
- drug-induced osteoporosis (93.8%)
- Ehlers-Danlos syndrome, fibronectinemic type (93.1%)
- renal osteodystrophy (91.2%)
- inherited thrombophilia (91.0%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.